Skip to content
- Endo M, et al. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japon Thoracic Oncology Group Lung Cancer 2006;52:135-40.
- Hoag JB, et al. Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res 2009;28:113.
- Hotta K, et al. lnterstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in 0kayama Lung. Cancer Study Group Cancer J 2005;11:417-24.
- Nalluri SR, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300(19):2277-85.
- Sandler AB, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009;27:1405-12.
- Tokano T, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104.
- Weiner SM, et al. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome – a single-centre experience and review of the literature. Nephrol Dial Transplant 2007;22:3631-7.
- Yang SH, et al. Pneumothorax after bevacizumab-containing chemotherapy: a case report. Jpn J Clin Oncol 2011;41(2):269-71.
- Barber NA, et al. Pulmonary toxicities from targeted therapies: a review. Target Oncol 2011;6(4):235-43.
- www.pneumotox.com
- Créquit P, et al. Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: a retrospective observational cohort study with a systematic literature review. J Thorac Oncol 2015;10(8):1148-55.
- Interiano RB, et al. Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors. J Pediatr Surg 2015.
- Schmitt L, et al. Vemurafenib-induced pulmonary injury. Onkologie 2013;36(11):685-6.
- Nishino M, et al. Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 2015;373(3):288-90.
- Albiges L, et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23(8):1943-53.